Roszet is a fixed-dose combination pill that contains rosuvastatin and ezetimibe as its active ingredients. It belongs to the cholesterol-lowering medication class and is prescribed to help reduce low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. In Hong Kong, Roszet is available by prescription only and is regulated by the Department of Health’s Drug Office.
Roszet lowers cholesterol through two complementary mechanisms:
Rosuvastatin is a high-potency HMG-CoA reductase inhibitor. By blocking this key enzyme in the liver, rosuvastatin reduces the synthesis of cholesterol, leading the liver to increase the number of LDL receptors on its surface. This enhances the clearance of LDL-C from the bloodstream.
Ezetimibe inhibits the intestinal protein NPC1L1, which is responsible for the absorption of dietary and biliary cholesterol. By limiting the amount of cholesterol that enters the bloodstream from the gut, ezetimibe adds an extra reduction in LDL-C levels.
Together, these actions provide an additive effect: rosuvastatin cuts the body’s internal production of cholesterol while ezetimibe limits external intake, resulting in a more pronounced drop in LDL-C than either drug alone.
Onset of lipid-lowering effect typically begins within 2 weeks, with the full effect reached after about 4-6 weeks of consistent dosing. The half-life of rosuvastatin is approximately 19 hours, allowing once-daily dosing, while ezetimibe’s half-life is roughly 22 hours.
Roszet is approved in Hong Kong for the following indications:
These uses align with the therapeutic goals of lowering cardiovascular risk in patients who require additional LDL-C reduction beyond what a statin alone can provide.
Current peer-reviewed evidence does not support any widely accepted off-label uses of the rosuvastatin/ezetimibe combination. Health professionals should reserve the medication for its approved lipid-lowering indications.
Absolute contraindications
Relative contraindications
Special populations
Major interactions
Cytochrome P450 3A4 inhibitors (e.g., clarithromycin, ritonavir) increase rosuvastatin plasma levels → higher risk of myopathy.
Cytochrome P450 2C9 inhibitors (e.g., fluconazole) may also raise rosuvastatin concentrations.
Fibrates (gemfibrozil) combined with rosuvastatin heighten the risk of muscle toxicity.
Moderate interactions
Warfarin: Rosuvastatin may modestly increase INR; monitor coagulation parameters.
Antacids containing aluminum or magnesium: Can reduce ezetimibe absorption; separate dosing by at least 2 hours.
This article provides educational information about Roszet and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Roszet may be combined with other lipid-modifying agents such as bile-acid sequestrants or PCSK9 inhibitors if LDL-C goals are not achieved with the fixed-dose combination alone. Co-administration should be supervised by a clinician to monitor for additive side effects, particularly muscle-related events.
Report any unexplained muscle aches, weakness, or dark urine to your healthcare provider promptly. The physician may order a creatine kinase (CK) test and consider dose reduction, temporary discontinuation, or switching to an alternative therapy.
Roszet is contraindicated in active liver disease or when liver enzymes are more than three times the upper limit of normal. Patients with chronic stable liver conditions should have liver function monitored regularly before and during therapy.
Roszet lowers LDL-C, total cholesterol, and non-HDL-C levels, while modestly raising HDL-C. When interpreting lipid panels, keep in mind that the medication may mask underlying dyslipidemia, and fasting samples are recommended for accurate assessment.
Roszet is a prescription medication; carrying it in its original pharmacy-labeled container with a copy of the prescription is advisable. In Hong Kong and most international airports, prescription drugs for personal use are permitted when properly documented.
Rosuvastatin’s absorption is not significantly affected by meals, and ezetimibe can be taken with or without food. Consistency in timing (e.g., always with dinner) helps maintain steady plasma levels.
Certain herbal products, such as St. John’s wort, can induce CYP enzymes and potentially reduce rosuvastatin concentrations, diminishing efficacy. Patients should disclose all supplement use to their clinician.
The fixed-dose combination offers the same active ingredients in a single pill, improving adherence and simplifying dosing. Pharmacologically, the effects are equivalent to taking the two drugs separately at the same doses.
While lipid reduction is evident within 4-6 weeks, the long-term cardiovascular benefit (reduced heart attack or stroke risk) becomes apparent over years of sustained therapy, as demonstrated in large outcome trials of statins and ezetimibe.
Statins can modestly increase serum uric acid, potentially exacerbating gout. Patients with gout should monitor uric acid levels and discuss any flare-ups with their healthcare provider, who may adjust therapy if needed.
